166P Insights in the mode of action of a T cell bispecific antibody in tumour bearing mice

ConclusionChanges observed in tumour bearing mice upon treatment with a tumour-targeted TCB suggest an early engagement of tumour resident T cells resulting in cytokine release locally and systemically within 2h after treatment, with homing and extravasation of inflammatory cells into the tumour progressively increasing 24h to 48h after treatment. This course of events is believed to be translatable to patients treated with TCBs.Legal entity responsible for the studyRoche Glycart AG.FundingRoche Glycart AG.DisclosureA.M. Giusti: Full / Part-time employment: Roche Glycart AG. J. Sam: Full / Part-time employment: Roche Glycart AG. M. Karagianni: Full / Part-time employment: Roche Glycart AG. A. Schneider: Full / Part-time employment: Roche Glycart AG.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research